Article citationsMore>>

Bolton, C.J., Khan, O.A., Liu, D., Pechman, K.R., Gifford, K.A., Hohman, T.J., et al. (2025) Combining Plasma P-Tau 231 and Glial Fibrillary Acidic Protein Produces Higher Discriminative Accuracy for Amyloid Positivity than Other Blood-Based Biomarker Combinations. Alzheimer’s & Dementia, 21, e70796.
https://doi.org/10.1002/alz.70796

has been cited by the following article:

• TITLE: Alzheimer’s Disease and Vascular Dementia: Diabetes-Related Cognitive Impairment Evaluation of Diagnostic Tools and Research Progress

  AUTHORS: Peifang Wang, Wen Zhong

  KEYWORDS: Diabetes-Related Cognitive Impairment, Alzheimer’s Disease, Vascular Cognitive Impairment, Scales, Biomarkers, Precision Diagnosis, Individualized Treatment

  JOURNAL NAME: Journal of Biosciences and Medicines, Vol.14 No.7, July 16, 2026

  ABSTRACT: Type 2 diabetes mellitus (T2DM) is closely related to cognitive dysfunction and an increased risk of dementia. Type 2 diabetes-related cognitive dysfunction (TDACD) is an important complication of the central nervous system of diabetes, and its diagnosis mode is highly dependent on neuropsychological scales. With the development of imaging and molecular detection technologies, marker systems represented by MRI, PET, and humoral biomarkers provide an objective basis for accurate diagnosis. This article aims to systematically review the diagnostic and differential diagnosis-related markers related to T2DM-related cognitive dysfunction or dementia, including neuropsychological scales, neuroimaging markers, and humoral biomarkers, and analyze their characteristics (such as sensitivity, specificity, predictive value, etc.), and provide ideas for accurate diagnosis of TDACD patients.